MAMarcelo R. de Amorim

Marcelo R. de Amorim

*This is an algorithmically generated author record based on publicly available information.

Marcelo R. de Amorim has a total of 36 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    NMR Analysis and Assignment of a Biosynthesis Gene Cluster for Trichokonins VI and VIII, Antiplasmodial Large Peptaibols Produced by a Trichoderma sp. Fungus

    by Ariane F. Bertonha, David E. Williams, Karen J. Nicacio, Marcelo R. de Amorim, Sydney M. Schoellhorn, Anna Caroline C. Aguiar, Talita Alvarenga Valdes, Giovana Rossi Mendes, Igor M. R. Moura, Lamonielli F. Michaliski, et al.

    Peptaibols are modified linear peptides that typically include an acyl fragment connected at the N-terminal moiety, a reduced acid extremity and α-aminoisobutyric acid residues as common features, as well as other structural modifications. Peptaibols very often display potent biological activity, in particular, antimicrobial activity. Trichokonins VI (1) and VIII (2) are large peptaibols composed of 20 amino acids, which were previously only characterized by analysis of MS/MS data. We herein report the first full characterization of trichokonins VI (1) and VIII (2) by analysis of NMR data, along with an analysis by electronic circular dichroism and HRMS/MS data. Also, full genome sequencing and analysis of Trichoderma sp. L2-2 allowed us to identify a peptaibol biosynthesis gene cluster and the proposal for a biosynthetic assembly of trichokonins VI and VIII. Trichokonins VI and VIII also demonstrated antiplasmodial activity at the submicromolar range against Plasmodium falciparum.


  • Open Access

    In Vitro and In Vivo Leishmanicidal Activity of Beauvericin

    by Virlânio A. de Oliveira Filho, Juliana R. Gubiani, Vitória D. Borgonovi, Felipe Hilário, Marcelo R. de Amorim, Karen Minori, Vitor K. S. Bertolini, Antonio G. Ferreira, Andressa R. Biz, Marcos A. Soares, et al.

    Leishmaniasis is a worldwide disease caused by more than 20 species of Leishmania parasites. Leishmania amazonensis and L. braziliensis are among the main causative agents of cutaneous leishmaniasis, presenting a broad spectrum of clinical forms. As these pathologies lead to unsatisfactory treatment outcomes, the discovery of alternative chemotherapeutic options is urgently required. In this investigation, a leishmanicidal bioassay-guided fractionation of the growth media extract produced by Aspergillus terreus P63 led to the isolation of the cyclic depsipeptide beauvericin (1). The viability of L. amazonensis, L. braziliensis and mammalian cells (macrophages and L929 fibroblasts) was assessed in 1 incubated cultures. Leishmania promastigotes were sensitive to 1, with EC50 values ranging from 0.7 to 1.3 μM. Microscopy analysis indicated that Leishmania spp. parasites showed morphological abnormalities in a dose-dependent manner in the presence of 1. L. amazonensis intracellular amastigotes were more sensitive to 1 than promastigotes (EC50 = 0.8 ± 0.1 μM), with a good selectivity index (22-30). 1 reduced the infectivity index at very low concentrations, maintaining the integrity of the primary murine host cell for up to the highest concentration tested for 1. In vivo assays of 1 conducted using BALB/c mice infected with stationary-phase promastigotes of L. amazonensis in the tail base presented a significant reduction in the lesion parasite load. A second round of in vivo assays was performed to assess the efficacy of the topical use of 1. The results demonstrated a significant decrease in the total ulcerated area of mice treated with 1 when compared with untreated animals. Our results present promising in vitro and in vivo leishmanicidal effects of beauvericin, emphasizing that systemic inoculation of 1 led to a decrease in the parasite load at the lesion site, whereas topical administration of 1 delayed the progression of leishmaniasis ulcers, a cure criterion established for cutaneous leishmaniasis management.


  • Open Access

    Structure and Biosynthesis of Perochalasins A–C, Open-Chain Merocytochalasans Produced by the Marine-Derived Fungus Peroneutypa sp. M16

    by Marcelo R. de Amorim, Sydney M. Schoellhorn, Camila de S. Barbosa, Giovana R. Mendes, Kamila de L. Macedo, Antonio G. Ferreira, Tiago Venâncio, Rafael V. C. Guido, Andrea N. L. Batista, João M. Batista, et al.

    Novel open-chain merocytochalasans, perochalasins A-C (1-3), containing an unusual N-O six-membered heterocyclic moiety, were isolated from cultures of the marine-derived Peroneutypa sp. M16 fungus, along with cytochalasin Z(27) (4), cytochalasin Z(28) (5), [12]-cytochalasin (6), and phenochalasin B (7). The structures of compounds 1-3 were established by analysis of the spectroscopic data. Full genome sequencing of Peroneutypa sp. M16 enabled the identification of a cytochalasan biosynthetic gene cluster and a proposal for the biosynthetic assembly of perochalasins. The proposal is supported by the nonenzymatic conversion of phenochalasin B (7) into 1-3, based on isotope-labeled hydroxylamine ((NH2OH)-N-15 and ND2OD) feeding studies in vivo and in vitro. In contrast to other merocytochalasans, these are the first cytochalasans confirmed to arise via nucleophilic addition and at a distinct location from the reactive macrocycle olefin, potentially expanding further the range of merocytochalasans to be discovered or engineered. Cytochalasin Z(27) (4) exhibited antiplasmodial activities in the low micromolar range against the chloroquine-sensitive Plasmodium falciparum 3D7 strain as well as against resistant strains of the parasite (Dd2, TM90C6B, and 3D7r_MMV848).